Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Alectinib (Alecensa) in Combination With Nivolumab (Opdivo) in the Treatment of Recurrent or Refractory Hepatocellular Carcinoma Patients Guided With Serum Level of RNase1 and Tumor Expression of PD-L1

NCT06354387 is registered in ClinicalTrials.gov with China Medical University Hospital as lead sponsor.

NCT NCT06354387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06354387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Alectinib (Alecensa) in Combination With Nivolumab (Opdivo) in the Treatment of Recurrent or Refractory Hepatocellular Carcinoma Patients Guided With Serum Level of RNase1 and Tumor Expression of PD-L1
Lead sponsor
China Medical University Hospital
Phase
Phase 1
Overall status
Completed
Start date
February 16, 2022
Completion date
February 28, 2026
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma